{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T11:56:01Z","timestamp":1792410961198,"version":"4.4.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["MVP-1273\/16"],"award-info":[{"award-number":["MVP-1273\/16"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000769","name":"University of Oxford","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.jinf.2021.01.030","type":"journal-article","created":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T17:33:03Z","timestamp":1613669583000},"page":"37-44","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Molecular characterization of invasive serogroup B Neisseria meningitidis isolates from Spain during 2015\u20132018: Evolution of the vaccine antigen factor H binding protein (FHbp)"],"prefix":"10.1016","volume":"82","author":[{"given":"Raquel","family":"Abad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Garc\u00eda-Amil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariadna","family":"Mart\u00edn-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio A","family":"V\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.jinf.2021.01.030_bib0001","doi-asserted-by":"crossref","first-page":"3876","DOI":"10.1016\/j.vaccine.2018.02.038","article-title":"Epidemiology, clinical presentation, risk factors, intensive care admission and outcomes of invasive meningococcal disease in England, 2010\u20132015","volume":"36","author":"Parikh","year":"2018","journal-title":"Vaccine"},{"issue":"23","key":"10.1016\/j.jinf.2021.01.030_bib0002","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1016\/j.vaccine.2014.02.068","article-title":"Variability of genes encoding surface proteins used as vaccine antigens in meningococcal endemic and epidemic strain panels from Norway","volume":"32","author":"Holst","year":"2014","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.jinf.2021.01.030_bib0003","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1600-0463.2012.02934.x","article-title":"Gene variability and degree of expression of vaccine candidate factor H binding protein in clinical isolates of Neisseria meningitidis","volume":"121","author":"Kelly","year":"2013","journal-title":"APMIS"},{"key":"10.1016\/j.jinf.2021.01.030_bib0004","doi-asserted-by":"crossref","first-page":"751","DOI":"10.3389\/fimmu.2019.00751","article-title":"The development of a vaccine against meningococcus B using reverse vaccinology","volume":"10","author":"Masignani","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jinf.2021.01.030_bib0005","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1016\/j.vaccine.2005.01.058","article-title":"The concept of \u201ctailor-made\u201d, protein-based, outer membrane vesicle vaccines against meningococcal disease","volume":"23","author":"Holst","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.jinf.2021.01.030_bib0006","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1128\/CVI.13.4.486-491.2006","article-title":"The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB","volume":"13","author":"Martin","year":"2006","journal-title":"Clin Vaccine Immunol"},{"issue":"30 Suppl 2","key":"10.1016\/j.jinf.2021.01.030_bib0007","doi-asserted-by":"crossref","first-page":"B87","DOI":"10.1016\/j.vaccine.2012.01.033","article-title":"The new multicomponent vaccine against meningococcal serogroup B, 4CMenB: immunological, functional and structural characterization of the antigens","volume":"30","author":"Serruto","year":"2012","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.jinf.2021.01.030_bib0008","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1080\/21645515.2017.1264750","article-title":"Meningococcal serogroup B vaccines: estimating breadth of coverage","volume":"13","author":"Donald","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.jinf.2021.01.030_bib0009","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1128\/CVI.00055-11","article-title":"Characterization of Neisseria meningitidis isolates that do not express the virulence factor and vaccine antigen factor H binding protein","volume":"18","author":"Lucidarme","year":"2011","journal-title":"Clin Vaccine Immunol"},{"issue":"6","key":"10.1016\/j.jinf.2021.01.030_bib0010","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1080\/00325481.2016.1203238","article-title":"Characteristics of a new meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp; Trumenba\u24c7)","volume":"128","author":"Gandhi","year":"2016","journal-title":"Postgrad Med"},{"issue":"6","key":"10.1016\/j.jinf.2021.01.030_bib0011","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00261-17","article-title":"Meningococcal antigen typing system (MATS)-based Neisseria meningitidis serogroup B coverage prediction for the MenB-4C vaccine in the United States","volume":"2","author":"Rajam","year":"2017","journal-title":"mSphere"},{"issue":"1","key":"10.1016\/j.jinf.2021.01.030_bib0012","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.vaccine.2013.03.063","article-title":"Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB)","volume":"32","author":"Bettinger","year":"2013","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.jinf.2021.01.030_bib0013","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1473-3099(13)70006-9","article-title":"Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment","volume":"13","author":"Vogel","year":"2013","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"10.1016\/j.jinf.2021.01.030_bib0014","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0150721","article-title":"Predicted strain coverage of a new meningococcal multicomponent vaccine (4CMenB) in Spain: analysis of the differences with other European countries","volume":"11","author":"Abad","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jinf.2021.01.030_bib0015","unstructured":"Casos notificados de enfermedad meningoc\u00f3cica e incidencia seg\u00fan serogrupo. Espa\u00f1a, temporadas epidemiol\u00f3gicas 1996-1997 a 2018-2019. RENAVE. Available on https:\/\/www.isciii.es\/QueHacemos\/Servicios\/VigilanciaSaludPublicaRENAVE\/EnfermedadesTransmisibles\/Documents\/archivos%20A-Z\/Enfer_Meningoc%C3%B3cica\/Tabla_Enfermedad%20meningoc%C3%B3cica%20en%20Espa%C3%B1a_%202020.pdf"},{"key":"10.1016\/j.jinf.2021.01.030_bib0016","unstructured":"Enfermedad meningoc\u00f3cica. Vigilancia de la temporada 2017-2018. Resultados de la Red Nacional de Vigilancia Epidemiol\u00f3gica. Available on https:\/\/www.isciii.es\/QueHacemos\/Servicios\/VigilanciaSaludPublicaRENAVE\/EnfermedadesTransmisibles\/Documents\/archivos%20A-Z\/Enfer_Meningoc%C3%B3cica\/RENAVE_EMI-2017-18.pdf"},{"issue":"5","key":"10.1016\/j.jinf.2021.01.030_bib0017","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1089\/cmb.2012.0021","article-title":"SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing","volume":"19","author":"Bankevich","year":"2012","journal-title":"J Comput Biol"},{"key":"10.1016\/j.jinf.2021.01.030_bib0018","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1186\/1471-2164-15-1138","article-title":"A gene-by-gene population genomics platform: de novo assembly, annotation and genealogical analysis of 108 representative Neisseria meningitidis genomes","volume":"15","author":"Bratcher","year":"2014","journal-title":"BMC Genom"},{"key":"10.1016\/j.jinf.2021.01.030_bib0019","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1073\/pnas.95.6.3140","article-title":"Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms","volume":"95","author":"Maiden","year":"1998","journal-title":"Proc Natl Acad Sci USA,"},{"key":"10.1016\/j.jinf.2021.01.030_bib0020","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1099\/mic.0.26131-0","article-title":"Antigenic diversity of meningococcal enterobactin receptor FetA, a vaccine component","volume":"149","author":"Thompson","year":"2003","journal-title":"Microbiology"},{"key":"10.1016\/j.jinf.2021.01.030_bib0021","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41541-019-0154-0","article-title":"Selection of diverse strains to assess broad coverage of the bivalent FHbp meningococcal B vaccine","volume":"5","author":"Harris","year":"2020","journal-title":"NPJ Vaccines"},{"issue":"7","key":"10.1016\/j.jinf.2021.01.030_bib0022","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.vaccine.2018.12.061","article-title":"Genetic meningococcal antigen typing system (gMATS): a genotyping tool that predicts 4CMenB strain coverage worldwide","volume":"37","author":"Muzzi","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.jinf.2021.01.030_bib0023","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1097\/INF.0b013e31829aa63b","article-title":"A multi-country evaluation of Neisseria meningitidis serogroup B factor H\u2013binding proteins and implications for vaccine coverage in different age groups","author":"Hoiseth","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jinf.2021.01.030_bib0024","series-title":"Poster presented at the 10th EMGM Meeting","article-title":"Clonal lineages evolution of serogroup B invasive meningococcal strains in Spain (2001-2007)","author":"Abad","year":"2009"},{"issue":"2","key":"10.1016\/j.jinf.2021.01.030_bib0025","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00036-18","article-title":"Predicting the susceptibility of meningococcal serogroup B isolates to bactericidal antibodies elicited by bivalent rLP2086, a novel prophylactic vaccine","volume":"9","author":"McNeil","year":"2018","journal-title":"MBio"},{"key":"10.1016\/j.jinf.2021.01.030_bib0026","doi-asserted-by":"crossref","first-page":"19490","DOI":"10.1073\/pnas.1013758107","article-title":"Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines","volume":"107","author":"Donnelly","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jinf.2021.01.030_bib0027","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1128\/CVI.00202-12","article-title":"Interlaboratory standardization of the sandwich enzyme-linked immunosorbent assay designed for MATS, a rapid, reproducible method for estimating the strain coverage of investigational vaccines","volume":"19","author":"Plikaytis","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.jinf.2021.01.030_bib0028","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1016\/j.vaccine.2013.08.006","article-title":"Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage","volume":"31","author":"Frosi","year":"2013","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.jinf.2021.01.030_bib0029","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1128\/CVI.00669-14","article-title":"A large portion of meningococcal antigen typing system-negative meningococcal strains from spain is killed by sera from adolescents and infants immunized with 4CMenB","volume":"22","author":"Abad","year":"2015","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.jinf.2021.01.030_bib0030","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1016\/j.vaccine.2015.04.015","article-title":"MATS: global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine","volume":"33","author":"Medini","year":"2015","journal-title":"Vaccine"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445321000876?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445321000876?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T21:31:18Z","timestamp":1759008678000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445321000876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0163445321000876"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2021.01.030","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular characterization of invasive serogroup B Neisseria meningitidis isolates from Spain during 2015\u20132018: Evolution of the vaccine antigen factor H binding protein (FHbp)","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2021.01.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd on behalf of The British Infection Association.","name":"copyright","label":"Copyright"}]}}